TNGX

Tango Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Tango Therapeutics sales and earnings growth
TNGX Growth
Low
  • Revenue Y/Y↑ 53.28%
  • EPS Y/Y↑ 21.55%
  • FCF Y/Y↓ -19.15%
Tango Therapeutics gross and profit margin trends
TNGX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -151.10%
  • ROIC↓ -48.80%
Tango Therapeutics net debt vs free cash flow
TNGX Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Tango Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗